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Background: Urothelial carcinoma of the upper urinary tract is relatively rare, occurring in 5% of all urothelial tumors.
Ureteral urothelial carcinoma is even less common than that of the renal pelvis, accounting for about 25% of all
upper urinary tract tumors. The aim of this study was to evaluate the clinical behavior, survival, recurrence and
prognostic information of primary ureteral urothelial carcinoma from our 11 years of experience at the Taipei Veterans
General Hospital.
Methods: We retrospectively reviewed 111 patients with ureteral urothelial carcinoma who had been treated in our
hospital between January 1993 and December 2003. Tumor staging was according to the 2002 AJCC TNM classification
and stage groupings. Patients with stage 0a and stage 0is were categorized as stage 0a/is, and patients with pathologic
T stage pTa and pTis were categorized as pTa/is for statistical analysis. The Kaplan-Meier method was used for
survival analysis.
Results: There were 69 males and 42 females, with a mean age of 70.5 ± 9.4 years at diagnosis. Of the 111
patients, 5 presented with stage 0a/is, 38 with stage I, 23 with stage II, 21 with stage III, and 24 with stage
IV. Nephroureterectomy with bladder cuff excision was performed in 78 patients, 12 patients received segmental
resection of the ureter, 4 received ureteroscopic laser coagulation, and 17 underwent chemotherapy or radiotherapy
or both. Tumors were located on the left side in 53 patients, on the right in 53, and bilaterally in 5. The most
frequent initial presenting symptom was gross hematuria (65%). The mean postoperative follow-up period was
49.3 months. Disease recurrence in the nephroureterectomy group occurred in 36 patients (46.2%), with 17
(21.8%) at the urinary bladder, 2 (2.6%) at the retroperitoneum, 1 (1.3%) at the contralateral ureter, 6 (7.7%) with
distant metastases to the lung, bone, distant lymph nodes or liver, and 10 (12.8%) at multiple sites. The 5-year
cancer-specific survival rate was 100% for pTa/is, 95.2% for pT1, 69.4% for pT2, and 43.8% for pT3. All 3 pT4
cases died of cancer in a median of 12 months. Significant prognostic factors for cancer-specific survival by univariate
analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
On multivariate analysis, only stage (p = 0.0001) and grade (p = 0.014) were significant for cancer-specific and
overall survival. Stage (p = 0.0001), pT (p =0.0001) and grade (p = 0.026) were also significant prognostic factors
of recurrence in multivariate analysis.
Conclusion: Our experience showed that patients with pTa/is and pT1 tumors treated with radical surgery have
excellent prognoses. Tumor stage and grade are the only significant prognostic factors for both cancer-specific and
overall survival. [J Chin Med Assoc 2005;68(11):522–530]
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Introduction
Urothelial carcinoma of the upper urinary tract is
relatively rare, occurring in 5% of all urothelial tumors.1
Ureteral carcinoma is even less common than that of
the renal pelvis, accounting for about 25% of all upper
urinary tract tumors.2,3 An unusually high incidence of
upper urinary tract urothelial carcinoma has been
reported in Taiwan, with the incidence of renal pelvis
transitional cell carcinoma varying from 15.4% to
83.3%.4 Many publications have provided the sur-
vival, recurrence and prognostic factors of urothelial
carcinoma of the ureter together with that of the renal
pelvis. However, different behaviors of urothelial
carcinoma of the renal pelvis and ureter have been
reported in terms of tumor invasion and prognosis.5
Ureteral urothelial carcinoma is associated with a
higher local or distant recurrence rate than urothelial
carcinoma of the renal pelvis. The aim of this study was
to evaluate the clinical behavior, survival, recurrence
and prognostic information of primary ureteral
urothelial carcinoma from our 11 years of experience
at the Taipei Veterans General Hospital
Methods
We retrospectively reviewed the medical records of
135 consecutive patients who had been treated at our
institution for urothelial carcinoma of the ureter
between January 1993 and December 2003. After
exclusion for synchronous tumor involvement of the
renal pelvis and those without complete medical
documents, 111 patients were included for analysis.
Demographic data, presenting symptoms, previous
history of urinary bladder or upper urinary tract
urothelial carcinoma, tumor location, treatment
modality, time to recurrence, and outcome were
recorded.
The pathologic stage of the tumor (pT) was assessed
according to the 2002 American Joint Committee on
Cancer TNM classification.6 Patients were also stratified
into stage 0a or stage 0is, and stage I, II, III, or IV
according to the stage groupings of the classification
system. Patients with stage 0a or stage 0is were
categorized as stage 0a/is, and patients with pTa or
pTis were categorized as pTa/is for statistical analysis
because patients with Ta and Tis were few and their
disease showed similar clinical behaviors. Tumor grade
was assessed according to the grading system established
by the World Health Organization.7
Time to recurrence was defined as the period from
the date of diagnosis to the time when recurrence was
demonstrated. Survival time was defined as the time
from the initial date of presentation to the end point,
including death or censoring.
Traditional prognostic factors that were analyzed
included age at diagnosis (older or younger than the
patients’ mean age), gender (male, female), presenting
symptoms (gross hematuria, asymptomatic, lower
abdominal or flank pain), pT stage (pTa/is, pT1–4),
stage groupings (stage 0a/is, stage I–IV), grade (1, 2,
3), laterality (left, right, bilateral), tumor location
(upper, middle, lower third of ureter, multiple sites),
and type of treatment (nephroureterectomy with
bladder cuff excision, nephron-sparing surgery, other
nonsurgical treatment).
Univariate and multivariate analyses were per-
formed using the Kaplan-Meier method with the log-
rank test and Cox proportional hazards regression
model to evaluate each prognostic factor with respect
to survival and recurrence. Differences were consi-
dered to be statistically significant when p was less
than 0.05.
Results
There were 69 men and 42 women (M:F, 1.6:1), with
a mean age at diagnosis of 70.5 ± 9.4 years (range,
38–91 years). Patients were followed up for a mean of
49.3 months (range, 1–136 months). Histopathologic
reports were available for 105 of the 111 patients; all
were urothelial carcinomas.
The initial presenting symptoms included gross
hematuria (72/111, 64.9%), incidental findings on
physical examination (21/111, 18.9%) and lower
abdominal or flank pain (18/111, 16.2%). Ureteral
tumors were located on the left side in 53 (47.7%)
patients, on the right in 53 (47.7%), and bilaterally in
5 (4.5%). The tumors were in the upper third of the
ureter in 24 (21.6%) patients, in the middle third in
37 (33.3%), in the lower third in 36 (32.4%), and at
multiple sites in 14 (12.6%). A previous history of
urothelial carcinoma of the urinary bladder or
contralateral ureter was present in 7 and 5 patients,
respectively. Concomitant bladder urothelial
carcinoma was seen in 12 patients when the ureteral
tumor was diagnosed. Among these 12 patients with
concomitant bladder cancer at the time of diagnosis
and the 7 with a previous history of bladder cancer,
7 had recurrence at the urinary bladder during follow-
up and were excluded from the group with subsequent
bladder recurrence due to the high recurrence rate of
bladder cancer. Tumor recurrence in the urinary
bladder occurred in 30 of the 111 patients (27.0%) in
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a median of 9 months (mean, 22.2 months; range,
1–100 months). The stage and grade of ureteral
urothelial carcinoma in the 111 patients are shown in
Table 1.
Of the 111 patients, 78 underwent nephro-
ureterectomy with bladder cuff excision. The pT
stage and grade in these 78 patients are shown in
Table 2. Five patients had grade 1 lesions, 2 of which
were pTa/is and 3 were pT1 tumors. Grade 2 lesions
were present in 41 patients, 17 of which were pT2–
pT4. Grade 3 lesions were observed in 32 patients,
30 of which were pT2–pT4. The disease recurred in
36 (46.2%) patients in a median of 10.5 months
(range, 1–100 months). The initial recurrences
occurred in the urinary bladder in 20 cases, locally in
the retroperitoneal tumor bed or lymph nodes in 5, in
the contralateral ureter in 3, and in distant metastases
in 8. In terms of the total number of recurrence
episodes, 23 patients had recurrences in the bladder, 7
had recurrences locally, 3 had recurrences in the
contralateral ureter, and 15 in distant organs such as
bone (3), lungs (3), distant lymph nodes (3) and at
multiple sites (6) including the liver.
In patients with a solitary kidney, and in those who
had a high risk of radical operation and distal ureteral
tumors, nephron-sparing procedures including seg-
mental resection of the ureter and laser coagulation of
the tumor under ureteroscopy were performed in 12
and 4 patients, respectively. Of the 12 patients who
underwent segmental resection of the ureter, 5
presented with grade 2 tumors while the others had
grade 3 tumors; 7 (58.3%) developed recurrence in the
remaining ipsilateral ureter and 2 had distant meta-
stases. Disease recurrence occurred in 8 of the 12 pa-
tients (66.7%) in a median of 22.5 months (range, 2–
57 months).
In the remaining 17 patients with advanced-stage
disease or severe comorbidity or who refused surgical
intervention, systemic chemotherapy, radiotherapy or
both was administered. Eleven (64.7%) died of the
cancer in a median of 7 months (range, 1–25 months),
and 4 (23.5%) died of non-cancer causes. Nine of 21
patients with pT3 tumor had adjuvant chemotherapy,
most with the MVAC (methotrexate, vinblastine,
doxorubicin, cisplatin) regimen. Adjuvant radiotherapy
was performed in 4 of the 21 pT3 patients. However,
8 of the 21 pT3 and all 3 of the pT4 patients did not
receive a complete course of adjuvant therapy after the
radical surgery due to severe side effects or refusal to
receive therapy.
Table 1. Stage and grade of ureteral urothelial carcinoma in 111 patients
Stage*
Grade, n (%)
Total, n (%)
1 2 3 Unknown
0a/is† 2 (1.8) 3 (2.7) 0 0 5 (4.5)
I 3 (2.7) 27 (24.3) 6 (5.4) 2 (1.8) 38 (34.2)
II 0 12 (10.8) 11 (9.9) 0 23 (20.7)
III 0 4 (3.6) 17 (15.3) 0 21 (18.9)
IV 0 5 (4.5) 15 (13.5) 4 (3.6) 24 (21.6)
Total, n (%) 5 (4.5) 51 (45.9) 49 (44.1) 6 (5.4) 111 (100)
*Stage groupings according to the American Joint Committee on Cancer TNM classification, 2002; †Stage 0a and stage 0is are combined and
categorized as stage 0a/is.
Table 2. Pathologic stage (pT) and grade of 78 patients treated with nephroureterectomy
Stage*
Grade, n (%)
Total, n (%)
1 2 3
pTa/is† 2 (2.6) 2 (2.6) 0 4 (5.1)
pT1 3 (3.8) 22 (28.2) 2 (2.6) 27 (34.6)
pT2 0 12 (15.4) 11 (14.1) 23 (29.5)
pT3 0 4 (5.1) 17 (21.8) 21 (26.9)
pT4 0 1 (1.3) 2 (2.6) 3 (3.8)
Total, n (%) 5 (6.4) 41 (52.6) 32 (41.0) 78 (100)
*Pathologic stage groupings according to the American Joint Committee on Cancer TNM classification, 2002; †pTa and pTis are combined and
categorized as pTa/is.
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The recurrence-free survival at 5 years for each of
the pT stages is shown in Table 3. In 4 patients with
pTa/is tumors, 2 had recurrences in the urinary bladder
at 4 and 37 months postoperatively. The recurrence-
free survival curves of patients at different pT stages are
illustrated in Figure 1. Two of the 3 pT4 patients had
recurrences 10 and 11 months after diagnosis and 1
died of cancer 9 months after disease onset without
disease relapse. In the univariate analysis, significant
prognostic factors for recurrence were stage groupings
(p = 0.00001), tumor grade (p = 0.0021) and type of
treatment (p = 0.00001) (Table 4). In the multivariate
analysis, the only significant predictors were pT stage
(p = 0.0001), stage groupings (p = 0.0001) and tumor
grade (p = 0.026) (Table 5).
The overall 5-year survival rate was 46.4%. The 1-,
3-, 5- and 10-year cancer-specific survival rates in the
nephroureterectomy group were 92.7%, 76.2%, 69.3%
and 66.3%, respectively. The 5-year cancer-specific
survival rates and 5-year overall survival rates according
to pT stage are shown in Table 6. The cancer-specific
survival curves of patients at different pT stages are
illustrated in Figure 2. All 3 pT4 patients died of disease
within 12 months. Prognostic factors for cancer-specific
survival by univariate analysis were pT stage (p =
0.00001), stage groupings (p = 0.00001), type of
treatment (p = 0.00001) and tumor grade (p = 0.0001)
(Table 7). The only factors significant for cancer-
specific survival on multivariate analysis were stage
groupings (p = 0.0001) and grade (p = 0.014) (Table 5).
Discussion
Urothelial carcinoma of the upper urinary tract is
relatively rare, comprising 5% of all urothelial tumors.1
Ureteral cancer is even less common than that of the
renal pelvis by a ratio of 1:3 to 1:4 and is reported to
exhibit significantly higher local or distant failure
rates.4,5 This study focused on urothelial carcinoma of
the ureter to provide survival and recurrence
information.
Among the 5 (6.4%) patients with grade 1 lesions
in the nephroureterectomy group, none were staged
beyond pT1. Grade 2 lesions occurred in 41 (52.6%)
patients and 17 (41.5%) were pT2–pT4 tumors. Thirty
of the 32 cases (93.8%) with grade 3 tumors were also
staged pT2–pT4. Only 4 (5.1%) patients were pTa/is.
In a study conducted by Babaian and Johnson,8 3 of
the 31 patients (9.8%) with primary ureteral carcinoma
had grade 1 tumors, 16 (51.6%) had grade 2, and 12
(38.7%) had grade 3 tumors. In a study by Heney et al9
of 60 patients with ureteral transitional cell carcinoma,
9 (15%) patients had grade 1 tumors and 17 (28.3%)
had stage 0 tumors. In a large series of 252 patients
with upper urinary tract transitional cell carcinoma,
15.4% of patients presented with pTa/is and 9.3%
were grade 1 tumors.3 Compared with these series, our
series demonstrated a relatively lower percentage of
grade 1 and pTa/is tumors. In addition, we found a
correlation between grade and pT stage, i.e. that
tumors at a lower stage tended to be lower grade
tumors while those at a higher stage tended to be
higher grade tumors (Table 2), as has been identified
in most of the previous series.
Table 3. Five-year recurrence-free rate by pathologic stage (pT)*
Stage Median 95% CI 5-year recurrence-free rate (%)
pTa/is 37.00 – 50.0
pT1 – – 70.4
pT2 50.00 4.05, 95.95 49.4
pT3 15.00 0.99, 29.01 27.7
pT4 10.00 – 0
*p = 0.0214. CI = confidence interval.
Figure 1. Recurrence-free survival curves by pathologic stage (pT).
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Table 4. Univariate analysis of potential prognostic factors for recurrence
Variable Mean ± SE Median % p
Age (yr) 0.7262
< 70.5 53.65 ± 7.96 23.00 39.62
> 70.5 53.62 ± 7.57 40.00 47.46
Gender 0.9562
Male 54.44 ± 7.26 27.00 43.48
Female 49.97 ± 7.47 36.00 44.19
Symptoms 0.2782
Hematuria 55.43 ± 7.12 36.00 45.21
Asymptomatic 62.85 ± 11.43 40.00 47.62
Pain 36.47 ± 11.31 4.00 33.33
pT 0.2727
pTa/is 55.80 ± 22.21 37.00 40.00
pT1 59.29 ± 8.09 40.00 49.02
pT2 66.24 ± 12.05 74.00 50.00
pT3 26.95 ± 6.42 15.00 24.00
pT4 26.57 ± 14.92 11.00 57.14
Stage groupings 0.00001
0a/is 55.80 ± 22.21 37.00 40.00
I 72.90 ± 8.79 100.00 58.97
II 69.12 ± 12.22 74.00 52.17
III 29.97 ± 7.07 15.00 23.81
IV 14.82 ± 6.33 – 29.17
Grade 0.0021
1 91.40 ± 12.16 – 80.00
2 68.40 ± 8.45 74.00 52.94
3 28.36 ± 4.87 15.00 30.00
Laterality 0.8351
Left 55.88 ± 8.09 23.00 41.51
Right 53.49 ± 7.62 39.00 46.30
Bilateral 18.90 ± 6.63 22.00 40.00
Tumor location 0.1585
Upper 3rd of ureter 62.93 ± 11.41 62.00 50.00
Middle 3rd of ureter 34.66 ± 7.43 14.00 36.84
Lower 3rd of ureter 69.39 ± 10.01 40.00 52.78
Multiple 36.96 ± 12.06 20.00 28.57
Type of treatment 0.00001
Radical 65.97 ± 6.68 50.00 50.00
Nephron-sparing 34.50 ± 7.98 23.00 33.33
Other 7.10 ± 2.83 – 27.78
pT = pathologic stage; SE = standard error.
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Nephroureterectomy with bladder cuff removal
remained the gold standard treatment for upper uri-
nary tract urothelial carcinoma, because of the high
recurrence rate in the remaining distal ureter of
16–58% and the multicentricity on the same side (15–
44%).3,10,11 Seventy-eight of our patients underwent
this radical surgery and achieved a 5-year recurrence-
free survival of 50% for pTa/is, 70.4% for pT1, 49.4%
for pT2 and 27.7% for pT3. The low 5-year recurrence-
free rate for pTa/is is attributable to the small case
number of this group. The 5-year cancer-specific
survival rates were 100% for pTa/is, 95.2% for pT1,
69.4% for pT2 and 43.8% for pT3. The 5-year survival
rate for each stage of the Heney et al9 series was 100%
for stage 0, 95% for stage A, 82% for stage B, 29% for
stage C and 0% for stage D. Mills and Vaughan12
reported their experience with 53 cases of carcinoma
of the ureter and showed the 5-year overall survival
rate for each stage to be 100% for stage 0, 80% for stage
A, 50% for stage B, 33.3% for stage C and 6.7% for
stage D. Many previous studies on transitional cell
carcinoma of both the renal pelvis and ureter were alsoFigure 2. Cancer-specific survival curves by pathologic stage (pT).
Table 5. Multivariate analysis of potential prognostic factors for recurrence and cancer-specific survival
Variable
Recurrence Cancer-specific survival
p RR 95% CI for RR p RR 95% CI for RR
Age 0.299 0.985 0.957, 1.014 0.655 1.009 0.970, 1.051
Gender 0.764 0.919 0.531, 1.592 0.696 1.196 0.488, 2.932
Symptoms 0.764 1.057 0.737, 1.515 0.973 1.009 0.608, 1.673
pT 0.0001 0.399 0.264, 0.602 0.103 1.749 0.892, 3.428
Stage groupings 0.0001 2.750 1.863, 4.058 0.0001 2.789 1.828, 4.256
Grade 0.026 1.880 1.079, 3.276 0.014 2.936 1.247, 6.913
Laterality 0.837 0.951 0.586, 1.542 0.657 1.187 0.557, 2.526
Tumor location 0.475 1.112 0.831, 1.486 0.708 1.095 0.681, 1.761
Type of treatment 0.584 1.171 0.665, 2.065 0.059 0.283 0.076, 1.051
CI = confidence interval; pT = pathologic stage; RR = risk ratio.
Table 6. Five-year cancer-specific survival and overall survival by pathologic stage (pT)
Stage
5-year cancer-specific survival 5-year overall survival rate
Median 95% CI Survival rate (%) Median 95% CI Survival rate (%)
pTa/is – – 100 – – 100
pT1 – – 95.2 – – 66.4
pT2 – – 69.4 – – 61.5
pT3 37 2, 72 43.8 37 21, 53 31.6
pT4 12 7, 17 0 12 7, 17 0
p 0.00001 0.00001
CI = confidence interval.
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Table 7. Univariate analysis of potential prognostic factors for cancer-specific survival
Variable Mean ± SE Median % p
Age (yr) 0.1824
< 70.5 102 ± 8 – 72.92
> 70.5 86 ± 8 – 63.64
Gender 0.5968
Male 92 ± 8 – 66.13
Female 93 ± 8 – 70.73
Symptoms 0.0945
Hematuria 96 ± 7 – 69.23
Asymptomatic 99 ± 9 – 80.00
Pain 58 ± 11 47 50.00
pT 0.00001
pTa/is – – 100
pT1 101 ± 7 – 78.26
pT2 106 ± 11 – 72.73
pT3 71 ± 13 37 52.17
pT4 16 ± 9 9 14.29
Stage groupings 0.00001
0a/is – – 100
I 121 ± 5 – 94.12
II 109 ± 10 – 76.19
III 77 ± 13 49 57.14
IV 26 ± 7 15 22.73
Grade 0.0001
1 – – 100
2 118 ± 6 – 84.09
3 73 ± 9 37 54.17
Laterality 0.9116
Left 87 ± 8 – 63.83
Right 97 ± 8 – 70.59
Bilateral 100 ± 20 – 80.00
Tumor location 0.0758
Upper 3rd of ureter 102 ± 11 – 78.26
Middle 3rd of ureter 73 ± 11 74 53.13
Lower 3rd of ureter 101 ± 8 – 77.14
Multiple 77 ± 16 – 61.54
Type of treatment 0.00001
Radical 101 ± 6 – 70.42
Nephron-sparing 65 ± 10 – 93.33
Other 33 ± 10 10 35.29
pT = pathologic stage; SE = standard error.
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available for comparison of the survival and recurrence
rates.3,5,13,14 The 5-year recurrence-free rate reported
by Hall et al3 was 73% for Ta/cis, 76% for pT1, 59% for
pT2, and 40% for pT3. The 5-year disease-specific
survival rate by tumor stage in several studies range
from 70% to 100% for pTa/is, 91% to 100% for pT1,
73% to 88% for pT2, and 41% to 61.9% for pT3.3,13,14
However, the calculation of recurrent survival rate did
not take recurrence in the urinary bladder into account.
In a study conducted in southern Taiwan by Lee et al15
in 1996, the 5-year survival rate was 100% in patients
with stages 0 and A upper urinary tract carcinoma, and
82%, 67% and 33%, respectively, for stage B, C and D
lesions.
Contrary to other experience, the present study
showed similar or lower survival rates by stage for 2
reasons. Firstly, ureteral urothelial carcinoma has been
reported to be more invasive, with higher local and
distant failure rates, than renal pelvis carcinoma. While
our patients all had carcinomas of the ureter, most
other studies involved tumors of both the ureter and
renal pelvis. Secondly, there was a lower rate of
completion of adjuvant systemic chemotherapy or
radiotherapy in our patients. Eleven of the 24 patients
(45.8%) with pT3 or pT4 tumors did not receive a
complete course of adjuvant systemic chemotherapy
or radiotherapy due to either severe side effects of the
therapy or patient refusal. Recurrence in the contra-
lateral ureter following radical surgery occurred in
3 patients in the current study (3.8%), as compared
with 2.5% and 2.9% in the studies of Krogh et al10 and
Charbit et al,16 respectively.
A high incidence of ipsilateral recurrence (23–
54%) after partial ureterectomy has been reported,11
and this was seen in our study in which 7 of the 12
patients (58.3%) who were treated with segmental
resection of the ureter had ipsilateral tumor recurrence
in the remaining urothelium. Zoretic and Gonzales,17
however, reported that only 1 of their 16 patients
(6.3%) who underwent segmental resection of the
ureter had ipsilateral tumor recurrence in the renal
pelvis (after a mean follow-up of 56 months). They
concluded that the indications for segmental resection
should be: (1) low-grade, low-stage transitional cell
carcinoma; (2) solitary kidney with a ureteral tumor;
(3) bilateral synchronous ureteral tumors; (4) poor
renal function; and (5) high-risk patients. However,
there are arguments against conservative surgery
regarding the difficulty in excluding coexisting tumors
on the same side and in determining stage-1 and
grade-1 tumors by intraoperative biopsy.18
Tumor grade and stage have traditionally been
reported as being major prognostic factors in patients
with upper urinary tract transitional cell carcinoma.2,3
Some series have reported that age,3 gender19 and
location in the renal pelvis5 are negative prognostic
factors, but these have not been confirmed.11 Based on
our findings, the prognostic factors for cancer-specific
survival by univariate analysis were pT, stage groupings,
type of treatment and tumor grade. The only factors
significant for cancer-specific survival on multivariate
analysis were stage groupings and grade. Significant
prognostic factors of recurrence, by univariate analysis,
were stage groupings, tumor grade and type of
treatment. Only stage groupings, grade and pT were
significant predictors of tumor recurrence by
multivariate analysis. Our findings corresponded with
previous reports on traditional prognostic factors.
From our 11-year experience in treating 111 patients
with primary ureteral urothelial carcinoma, we conclude
that pTa/is and pT1 stage tumors treated with radical
surgery have an excellent prognosis. Tumor stage and
grade are the only significant prognostic factors for
both cancer-specific and overall survivals.
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